KAHR-Medical Ltd.

KAHR Medical Ltd. is a clinical-stage biotechnology company based in Jerusalem, Israel, founded in 2005. The company focuses on developing innovative fusion protein pharmaceuticals and immune-recruiting therapies aimed at treating cancer. KAHR Medical is advancing its pipeline through clinical trials, particularly targeting cancers with high mortality rates, such as colorectal and lung cancer.

The company's portfolio includes several drug candidates, primarily fusion proteins designed for oncology applications. Notable candidates include DSP107, which is in phase 1/2 trials and has shown promising results in colorectal cancer, and other candidates like DSP105, DSP106, and DSP502, which are in various stages of development. KAHR Medical emphasizes its technology platform that features bispecific and bifunctional fusion proteins, enhancing T-cell activity and immune responses against tumors.